Pre-exposure Prophylaxis for HIV Prevention Preferences Among Young Adult African American Men Who Have Sex with Men

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2018 Dec 29

PMID 30592756

Citations 25

Authors

Rupa R Patel

John S Crane

Julia Lopez

Philip A Chan

Albert Y Liu

Rubabin Tooba

Aimee S James

Affiliations

Soon will be listed here.

Abstract

Pre-exposure prophylaxis (PrEP) is effective in preventing HIV infections among men who have sex with men (MSM). PrEP uptake and adherence remain low and product preferences are unknown, especially among young African American MSM who are most at-risk. We conducted 26 qualitative interviews from 2014-2016 among young adult HIV-negative African American MSM regarding PrEP product preferences in Missouri. While the pill and injectable were most liked of all modalities, about a quarter preferred rectal products or patches. Most participants preferred a long-acting injectable (LAI) to daily oral pills due to better medication adherence and a dislike for taking pills. Many participants preferred daily oral pills to on-demand oral PrEP due to the inability to predict sex and the perception that insufficient time or medication would not achieve HIV protection with on-demand. A fear of needles and the perception that there would not be therapeutic levels for a long duration were concerns with injectable PrEP. Study findings highlight the need for a range of prevention options for African American MSM and can inform PrEP product development as well as dissemination and implementation efforts.

Citing Articles

Protocol: the American Women: Assessing Risk Epidemiologically (AWARE) cohort study.

Schnall R, Kempf M, Phillips 2nd G, Dionne J, Wingood G, Long D BMC Public Health. 2024; 24(1):3422.

PMID: 39695485 PMC: 11653693. DOI: 10.1186/s12889-024-20810-4.

HIV Care Preferences among Young People Living with HIV in Lesotho: A Secondary Data Analysis of the PEBRA Cluster Randomized Trial.

Seiler O, Kopo M, Kao M, Lejone T, Tschumi N, Glass T AIDS Res Treat. 2024; 2023:8124192.

PMID: 39691584 PMC: 11651754. DOI: 10.1155/2023/8124192.

Reconciling advantages and difficulties: knowledge and perceptions of event-driven PrEP among young people.

Deus L, Ferraz D, Santos L, Grangeiro A, Dourado I, Couto M Rev Saude Publica. 2024; 58(suppl 1):13s.

PMID: 39417509 PMC: 11573368. DOI: 10.11606/s1518-8787.2020054005729.

Supporting Pre-Exposure Prophylaxis Uptake: Exploring Social Network Characteristics among Black Women and Acceptability of Social Network Strategies.

Johnson A, Devlin S, Hill M, Ott E, Friedman E, Haider S Healthcare (Basel). 2024; 12(17).

PMID: 39273793 PMC: 11395160. DOI: 10.3390/healthcare12171769.

Barriers and facilitators to pre-exposure prophylaxis uptake among Black/African American men who have sex with other men in Iowa: COM-B model analysis.

Adeagbo O Ther Adv Infect Dis. 2024; 11:20499361241267151.

PMID: 39070701 PMC: 11282522. DOI: 10.1177/20499361241267151.

References

Hendrix C, Andrade A, Bumpus N, Kashuba A, Marzinke M, Moore A . Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine After Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks (HPTN 066). AIDS Res Hum Retroviruses. 2015; 32(1):32-43. PMC: 4692123. DOI: 10.1089/AID.2015.0182. View

Elsesser S, Oldenburg C, Biello K, Mimiaga M, Safren S, Egan J . Seasons of Risk: Anticipated Behavior on Vacation and Interest in Episodic Antiretroviral Pre-exposure Prophylaxis (PrEP) Among a Large National Sample of U.S. Men Who have Sex with Men (MSM). AIDS Behav. 2015; 20(7):1400-7. PMC: 4854804. DOI: 10.1007/s10461-015-1238-0. View

Hosek S, Rudy B, Landovitz R, Kapogiannis B, Siberry G, Rutledge B . An HIV Preexposure Prophylaxis Demonstration Project and Safety Study for Young MSM. J Acquir Immune Defic Syndr. 2016; 74(1):21-29. PMC: 5140725. DOI: 10.1097/QAI.0000000000001179. View

Carballo-Dieguez A, Giguere R, Dolezal C, Leu C, Balan I, Brown 3rd W . Preference of Oral Tenofovir Disoproxil Fumarate/Emtricitabine Versus Rectal Tenofovir Reduced-Glycerin 1% Gel Regimens for HIV Prevention Among Cisgender Men and Transgender Women Who Engage in Receptive Anal Intercourse with Men. AIDS Behav. 2017; 21(12):3336-3345. PMC: 5856109. DOI: 10.1007/s10461-017-1969-1. View

Closson E, Mitty J, Malone J, Mayer K, Mimiaga M . Exploring strategies for PrEP adherence and dosing preferences in the context of sexualized recreational drug use among MSM: a qualitative study. AIDS Care. 2017; 30(2):191-198. DOI: 10.1080/09540121.2017.1360992. View

Biello K, Hosek S, Drucker M, Belzer M, Mimiaga M, Marrow E . Preferences for Injectable PrEP Among Young U.S. Cisgender Men and Transgender Women and Men Who Have Sex with Men. Arch Sex Behav. 2017; 47(7):2101-2107. DOI: 10.1007/s10508-017-1049-7. View

Schlesinger E, Johengen D, Luecke E, Rothrock G, McGowan I, van der Straten A . A Tunable, Biodegradable, Thin-Film Polymer Device as a Long-Acting Implant Delivering Tenofovir Alafenamide Fumarate for HIV Pre-exposure Prophylaxis. Pharm Res. 2016; 33(7):1649-56. PMC: 4892981. DOI: 10.1007/s11095-016-1904-6. View

Rolle C, Rosenberg E, Siegler A, Sanchez T, Luisi N, Weiss K . Challenges in Translating PrEP Interest Into Uptake in an Observational Study of Young Black MSM. J Acquir Immune Defic Syndr. 2017; 76(3):250-258. PMC: 5634925. DOI: 10.1097/QAI.0000000000001497. View

Koechlin F, Fonner V, Dalglish S, OReilly K, Baggaley R, Grant R . Values and Preferences on the Use of Oral Pre-exposure Prophylaxis (PrEP) for HIV Prevention Among Multiple Populations: A Systematic Review of the Literature. AIDS Behav. 2016; 21(5):1325-1335. PMC: 5378753. DOI: 10.1007/s10461-016-1627-z. View

10.

Molina J, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I . On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. N Engl J Med. 2015; 373(23):2237-46. DOI: 10.1056/NEJMoa1506273. View

11.

Markowitz M, Frank I, Grant R, Mayer K, Elion R, Goldstein D . Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial. Lancet HIV. 2017; 4(8):e331-e340. DOI: 10.1016/S2352-3018(17)30068-1. View

12.

Hoots B, Finlayson T, Nerlander L, Paz-Bailey G . Willingness to Take, Use of, and Indications for Pre-exposure Prophylaxis Among Men Who Have Sex With Men-20 US Cities, 2014. Clin Infect Dis. 2016; 63(5):672-7. PMC: 5009903. DOI: 10.1093/cid/ciw367. View

13.

Thigpen M, Kebaabetswe P, Paxton L, Smith D, Rose C, Segolodi T . Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012; 367(5):423-34. DOI: 10.1056/NEJMoa1110711. View

14.

Eaton L, Matthews D, Driffin D, Bukowski L, Wilson P, Stall R . A Multi-US City Assessment of Awareness and Uptake of Pre-exposure Prophylaxis (PrEP) for HIV Prevention Among Black Men and Transgender Women Who Have Sex with Men. Prev Sci. 2017; 18(5):505-516. PMC: 5926200. DOI: 10.1007/s11121-017-0756-6. View

15.

Lelutiu-Weinberger C, Golub S . Enhancing PrEP Access for Black and Latino Men Who Have Sex With Men. J Acquir Immune Defic Syndr. 2016; 73(5):547-555. PMC: 5110381. DOI: 10.1097/QAI.0000000000001140. View

16.

Grant R, Mannheimer S, Hughes J, Hirsch-Moverman Y, Loquere A, Chitwarakorn A . Daily and Nondaily Oral Preexposure Prophylaxis in Men and Transgender Women Who Have Sex With Men: The Human Immunodeficiency Virus Prevention Trials Network 067/ADAPT Study. Clin Infect Dis. 2018; 66(11):1712-1721. PMC: 5961078. DOI: 10.1093/cid/cix1086. View

17.

Kubicek K, Arauz-Cuadra C, Kipke M . Attitudes and perceptions of biomedical HIV prevention methods: voices from young men who have sex with men. Arch Sex Behav. 2015; 44(2):487-97. PMC: 4322392. DOI: 10.1007/s10508-014-0398-8. View

18.

Grant R, Lama J, Anderson P, McMahan V, Liu A, Vargas L . Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010; 363(27):2587-99. PMC: 3079639. DOI: 10.1056/NEJMoa1011205. View

19.

Molina J, Charreau I, Spire B, Cotte L, Chas J, Capitant C . Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study. Lancet HIV. 2017; 4(9):e402-e410. DOI: 10.1016/S2352-3018(17)30089-9. View

20.

Smith D, Van Handel M, Grey J . Estimates of adults with indications for HIV pre-exposure prophylaxis by jurisdiction, transmission risk group, and race/ethnicity, United States, 2015. Ann Epidemiol. 2018; 28(12):850-857.e9. DOI: 10.1016/j.annepidem.2018.05.003. View